
This site is no longer maintained as of January 16th, 2013. Due to the increased security risks of this out-dated application , it will be decommissioned July 1st 2013. Please migrate use over to its replacement http://bioconnect.bio5.org. Direct questions and concerns to bio5admin@bio5.org. Thank you.
My laboratory focuses on the molecular origins of human cancer. More specifically, my laboratory has 3 inter-related research objectives based on the underlying concept that developing an in-depth understanding of epigenetic mechanisms that govern cell fate will allow for the development of more effective strategies for the prevention, treatment, and cure of cancer. First, we wish to identify which epigenetic mechanisms participate in the transcriptional control of genes important to growth and differentiation. Second, we seek to determine how these epigenetic mechanisms, and therefore epigenetic homeostasis, become compromised during oncogenesis. Third, using our new and more complete understanding of epigenetic control of the genome, we are developing rational new therapeutic strategies that seek to repair these defects in the cancer cell and transcriptionally reprogram the malignant cancer cell to a benign state. To reach our objectives, a variety of in vitro models of cancer have been developed to address emerging hypotheses that are inferred from the literature in basic and clinical science as well as our own data. Results from these in vitro studies are then translated to the clinical situation to determine their meaning in the actual clinical face of the disease. Similarly, we attempt to take information obtained from the genome-wide assessment of clinical specimens in order to help guide our thinking and develop new hypotheses that can be tested experimentally in our in vitro models.